C almodulin (CaM) is an essential Ca 2+ sensing, signaltransducing protein. Calcium-induced activation of CaM regulates many calcium-dependent processes and modulates the function of cardiac ion channels, including the long QT syndrome (LQTS)-associated CACNA1C-encoded Ca V 1.2 calcium channel and SCN5A-encoded Na V 1.5 sodium channel, as well as the catecholaminergic polymorphic ventricular tachycardia (CPVT)-associated RYR2-encoded ryanodine receptor. 1-3 Interestingly, there are 3 calmodulin genes, CALM1 (chr14q31), CALM2 (chr2p21), and CALM3 (chr19q13), 4 with unique nucleotide sequences that all encode for a completely identical 149 amino acid CaM protein, 5,6 which are expressed differentially in the human heart. 7 Variants in all 3 of the calmodulin genes (CALM1, CALM2, and CALM3) have been described recently in LQTS. 7-9 LQTS is a disorder of ventricular myocardial repolarization characterized by the prolongation of the heart-rate corrected QT interval (QTc) on a resting ECG, manifesting clinically as syncope, seizures, or sudden death in the setting of a structurally normal heart. In 2013, whole-exome sequencing (WES) was Background-Calmodulin (CaM) is encoded by 3 genes, CALM1, CALM2, and CALM3, all of which harbor pathogenic variants linked to long QT syndrome (LQTS) with early and severe expressivity. These LQTS-causative variants reduce CaM affinity to Ca 2+ and alter the properties of the cardiac L-type calcium channel (Ca V 1.2). CaM also modulates Na V 1.5 and the ryanodine receptor, RyR2. All these interactions may play a role in disease pathogenesis. Here, we determine the spectrum and prevalence of pathogenic CaM variants in a cohort of genetically elusive LQTS, and functionally characterize the novel variants. Methods and Results-Thirty-eight genetically elusive LQTS cases underwent whole-exome sequencing to identify CaM variants. Nonsynonymous CaM variants were over-represented significantly in this heretofore LQTS cohort (13.2%) compared with exome aggregation consortium (0.04%; P<0.0001). When the clinical sequelae of these 5 CaM-positive cases were compared with the 33 CaM-negative cases, CaM-positive cases had a more severe phenotype with an average age of onset of 10 months, an average corrected QT interval of 676 ms, and a high prevalence of cardiac arrest. Functional characterization of 1 novel variant, E141G-CaM, revealed an 11-fold reduction in Ca 2+ -binding affinity and a functionally dominant loss of inactivation in Ca V 1.2, mild accentuation in Na V 1.5 late current, but no effect on intracellular RyR2mediated calcium release. Conclusions-Overall, 13% of our genetically elusive LQTS cohort harbored nonsynonymous variants in CaM. Genetic testing of CALM1-3 should be pursued for individuals with LQTS, especially those with early childhood cardiac arrest, extreme QT prolongation, and a negative family history. (Circ Cardiovasc Genet. 2016;9:136-146.
WES With Targeted Calmodulin Gene Analysis
All 38 patients with LQTS underwent WES and subsequent calmodulin (CaM) gene (CALM1, CALM2, and CALM3)-specific analysis. Briefly, paired-end libraries were prepared using the manufacturer's protocol (Illumina, San Diego, CA and Agilent, Santa Clara, CA) using the Bravo liquid handler from Agilent. Whole-exome capture was carried out using the protocol for Agilent's SureSelect Human All Exon v4+UTRs kit. Exome libraries were loaded onto TruSeq Rapid run paired-end flow cells at concentrations of 9 pmol/L to generate cluster densities of 600 000 to 800 000 per mm 2 using Illumina's standard protocol using the Illumina cBot and TruSeq Rapid Paired end cluster kit version 1. The flow cells were sequenced as 100×2 paired end reads on an Illumina HiSeq 2500 using TruSeq Rapid SBS kit version 1 and HiSeq data collection version 2.0.12.0 software. Base calling was performed using Illumina's RTA version 1.17.21.3.
The Illumina paired end reads were aligned to the hg19 reference genome using Novoalign 2.08 (http://novocraft.com) followed by the sorting and marking of duplicate reads using Picard (http://picard. sourceforge.net). Local realignment of insertions/deletions and base quality score recalibration were then performed using the Genome Analysis Toolkit 2.7-4. 12 Single-nucleotide variants and insertions/ deletions were called across all the samples simultaneously using Genome Analysis Toolkit's Unified Genotyper with variant quality score recalibration. 13 After the Mayo Clinic bioinformatics pipeline analysis, the data were provided in comprehensive Microsoft Excel (Redmond, WA) spreadsheet with all the identified variants across WES samples. Using filter functions in Microsoft Excel, we searched for variants within CALM1 (NM_006888), CALM2 (NM_001743), and CALM3 (NM_005184) that had a genotype call quality score of >20 and a read depth of >10. To be considered as a putative pathogenic variant, the identified CaM variants had to be (1) nonsynonymous (amino acid altering), (2) involve a highly conserved amino acid, and (3) absent in the Exome Aggregation Consortium (ExAC, n=60 706) database. 14 All CaM variants identified through WES were Sanger sequence verified. Primer sequences and conditions are available on request.
Functional Analysis
The novel CaM variant (p.E141G) was characterized functionally using Ca 2+ -binding assays and patch-clamp electrophysiological recording to assess its pathogenicity.
Generation of Recombinant CaM and Measurement of Ca 2+ Binding to CaM
Wild-type (WT) and mutant CaM proteins were prepared, and the Ca 2+ affinities for WT-and E141G-CaM were determined using previously described methods. 7
CaM Mammalian Expression Vectors and Site-Directed Mutagenesis
The EGFP-HA-CaM (enhanced green florescent protein [EGFP]) vector, kindly provided by Dr Emanuel Strehler, Mayo Clinic, Rochester, MN, was used for the heterologous expression electrophysiology studies of Ca V 1.2 and Na V 1.5 in TSA201 cells. The p.E141G missense variant was engineered into EGFP-HA-CaM vector using primers containing the missense variant (available on request) in combination with the Quikchange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The integrity of all constructs was verified by DNA sequencing.
Heterologous Expression and Electrophysiological Analysis of Ca V 1.2 Coexpressed With WT-or E141G-CaM
The constructs utilized to recapitulate Ca V 1.2 have been described previously. 15 TSA201 cells were cultured in Dulbecco Modification of Eagle's Medium supplemented with 10% fetal bovine serum, 1.0% l-glutamine, and 1.2% penicillin/streptomycin solution in a 5% CO 2 incubator at 37°C. Heterologous expression of Ca V 1.2 was accomplished by cotransfecting 1-μg CACNA1C ([{EYFP}Nα1c,77] in pcDNA), 15 1-μg CACNB2b (in pIRES2-dsRED2), 15 and 1-μg CACNA2D1 (in pcDNA3.1) 15 vectors with either 0.5 μg a green fluorescent protein empty vector (GFP-EV; kindly provided by Dr Gianrico Farrugia, Mayo Clinic, Rochester, MN), EGFP-HA-CaM-WT or EGFP-HA-CaM-E141G vectors using 9-μL lipofectamine 2000 (Invitrogen, Carlsbad, CA). The media was replaced with fresh OPTI-MEM after 4 to 6 hours. Transfected TSA201 cells were cultured in OPTI-MEM and incubated for 48 hours and cells exhibiting green, red, and yellow fluorescence were selected for electrophysiological experiments. Standard whole-cell patch-clamp technique was used to measure Ca V 1.2 WT currents coexpressed with WT-or E141G-CaM at room temperature (22-24°C) as described previously. 15 In addition, we also examined persistent I CaL current, which was measured at the end of a 500-ms long depolarization.
Animal Use and Experiments in Ventricular Myocytes
The use of animals in this study was approved by the Animal Care and Use Committees of Vanderbilt University, Nashville, TN, and performed in accordance with National Institutes of Health guidelines. Single ventricular myocytes from 10-to 16-week-old C57BL/6 mice were isolated by enzymatic digestion using collagenase as previously described. 16 Inactivation of Ca V 1.2 current was studied in freshly isolated murine ventricular myocytes using whole-cell patchclamp technique. CaM (total concentration 6 μmol/L for all experiments) was added to pipette solution and then dialyzed into the cell via patch pipette. Currents were elicited with 500-ms depolarizing pulses to 0 mV from holding potential of −70 mV applied every 2 minutes to track the effect of CaM over time, as it diffuses into the cell. Usually, the effect of CaM on inactivation reached its maximum 4 to 6 minutes after start of dialysis; 15-ms prepulses to −40 mV were applied before the test pulse to inactivate Na + currents. Cells were pretreated with ryanodine (50 μmol/L) and thapsigargin (10 μmol/L) for 30 minutes before experiment to prevent sarcoplasmic reticulum (SR) Ca 2+ release. Experiments were conducted at room temperature. For mixing studies, a mixture of 75% of WT CaM and 25% of mutant CaM (total CaM concentration 6 μmol/L) was used. Tau values represent monoexponential fit of the last 350 ms of the current during depolarizing step. In addition, Ca 2+ spark measurements to examine RyR2 activity were completed as previously described. 3
Heterologous Expression and Electrophysiological Analysis of Na V 1.5 Coexpressed With WT-or E141G-CaM
To recapitulate the SCN5A-encoded Na V 1.5 sodium channel, 1 μg of the human cardiac voltage-dependent Na + channel α subunit (H558/ Q1077del, Genbank accession no. AY148488) in the pcDNA3 vector (Invitrogen) was cotransfected with either 0.5-μg GFP-EV, EGFP-HA-CaM-WT, EGFP-HA-CaM-E141G, or 0.25-μg EGFP-HA-CaM-WT+0.25-μg EGFP-HA-CaM-E141G with the use of 4-μL lipofectamine in TSA201 cells. Transfected TSA201 cells were cultured in OPTI-MEM (Gibco, Carlsbad, CA) and incubated for 24 hours after transfection and cells exhibiting green fluorescence were selected for electrophysiological experiments. Standard whole-cell patch-clamp technique was used to measure Na V 1.5 WT currents coexpressed with WT-CaM, E141G-CaM, or WT-CaM+E141G-CaM (to mimic the heterozygous state of the patient) at room temperature as previously described. 17 Late I Na was measured at the end of 700-ms long depolarization.
Statistical Analysis
Data are presented as mean values±SEM or ±95% confidence intervals. 
Results

Genetic Analysis
Our genetically elusive LQTS cohort consisted of 38 individuals (42% males, average age at diagnosis was 20±18 years, 24% were <5 years of age). The average QTc was 535±13 ms, 39% experienced syncope, 34% cardiac arrest, and 37% had a positive family history of cardiac arrhythmias or sudden unexplained death (Table 1) .
WES revealed 4 CaM missense variants, p.D130G (c.389A>G, CALM2), p.D130V (c.389A>T, CALM2), p.E141G (c.422A>G, CALM1), and 2 cases with p.F142L (c.426C>G, CALM1), in a total of 5 of 38 cases (13.2%; Table 2, Figure 1 ). Both p.D130V and p.E141G represent novel CaM variants. The p.D130G and p.F142L CaM variants have been characterized functionally and described previously as LQTS-susceptibility variants ( Table 2) . 7, 10, 11, 18 Our previously discovered CALM3variant-positive child was not included in this cohort of unrelated cases as the child's variant had been discovered by WES and genomic triangulation (proband/parent trio) akin to the previous CALM1 and CALM2 discoveries. 9 The p.D130G variant was identified in a female born at term that was noted to have bradycardia ( Figure 1 ). An ECG, recorded 12 hours after birth, revealed a QTc of 740 ms and 2:1 atrioventricular (AV) block. She was treated with β-blockers, phenytoin, spironolactone, potassium, and a single chamber pacemaker in the first week of life. At the age of 6 years, a single-chamber implantable cardioverter-defibrillator was implanted and β-blocker therapy continued. At the age of 11 and 14 years, she experienced appropriate implantable cardioverter-defibrillator discharges for ventricular fibrillation (VF). The family history was negative. Parental DNA was unavailable.
The p.D130V variant was identified in a male born with 2:1 AV block in utero ( Figure 1 ). QT prolongation (QTc=800 ms) was documented at birth, macroscopic T-wave alternans was observed, and β-blocker therapy was initiated. Echocardiograms at the first month of life showed restrictive cardiomyopathy with borderline systolic function. In his second month of life, he developed torsades de pointes, and subsequently had a left T2-T4 sympathetic denervation and minimally invasive epicardial implantable cardioverter-defibrillator. His β-blocker was combined with sodium channel blockers. At the age of 6 years, he experienced an appropriate VF-terminating shock after a medication dose change by his parents. His echocardiograms demonstrated dilated cardiomyopathy with hypertrabeculation and continued QT prolongation. At the age of 7 years, he had an additional VF-terminating shock after missing a single β-blocker dose. The family history was negative. The p.D130V was absent in both parents, thus confirming a de novo occurrence in the child.
The p.E141G variant was identified in a male with his first unwitnessed syncopal event at 3 years of age from which he was found unconscious and spontaneously recovered ( Figure 1 ). He experienced his first sudden cardiac arrest at 4 years of age in which cardiopulmonary resuscitation was initiated, and after 30 minutes, consciousness was regained. After his sudden cardiac arrest, an ECG revealed a QTc of 610 ms, and he was treated subsequently with β-blockers and sodium channel blockers. His QT prolongation has persisted; however, the index case is now 11-years of age and has not experienced an episode since the initiation of treatment. An echocardiogram revealed mild LV dilation; however, the cardiac valves and structure were normal. In addition, it was noted that he has speech and motor skill delay. He has a negative family history. The p.E141G was not identified in either parent confirming a de novo occurrence in the child.
The p.F142L variant was identified in a female. Her ECG shortly after birth showed a QTc of 612 ms and 2:1 AV block ( Figure 1 ). Her initial treatment consisted of β-blockers, and at 19 months a dual chamber pacemaker was implanted. Shortly thereafter, she had sudden cardiac arrest which caused anoxic brain injury and seizure-like syncopal episodes. After the initiation of this genetic investigation, the patient died suddenly. She was brought to the emergency room for altered mental status. Echocardiogram revealed severely diminished left ventricular systolic dysfunction. Soon after arrival, she deteriorated to VF and was unable to be resuscitated. Her autopsy revealed cardiomegaly with dilation and hypertrophy. She had no family history of arrhythmias, and her mother was negative for the p.F142L variant. Her father's sample was unavailable.
This p.F142L variant was also identified in a male. He was delivered at term, and bradycardia was noted. This prompted an ECG, which revealed a QTc of 620 ms. He was treated with β-blockers and had a pacemaker placed for atrial pacing. This combination therapy was associated with an attenuation of his QTc down to 540 ms. Shortly after recruitment into our study at 1 year and 3 months of age, this patient died suddenly. He was placed for a nap and was found gasping for air, unconscious and blue, and unfortunately was unable to be resuscitated. Interrogation of his pacemaker showed sinus rhythm with 1:1 conduction just before a period of fast VF. He had no previous recorded events on his pacemaker. ECGs were obtained for the parents and siblings, all were normal, and both parents were negative for the p.F142L variant, supporting de novo occurrence.
Over-Representation of CaM Variants in LQTS Versus ExAC
Nonsynonymous CaM variants were over-represented significantly in our LQTS cohort (5/38; 13.2%) compared with ExAC (23/60 706; 0.04%, P<0.0001; Figure 1 ). The 21 rare nonsynonymous CaM variants identified in ExAC are shown in Figure 1 and Table I in the Data Supplement. Interestingly, all 8 of the pathogenic CaM residues (D96, N98, D130, D132, D134, Q136, E141, and F142) 7-9 that are affected in patients with LQTS reside within 1 of the 4 EF hands, where Ca 2+ binds to CaM. Specifically, these pathogenic variants localize to either the third (D96 and N98) or fourth (D130, D134, Q136, E141, and F142) EF hand located in the C domain ( Figure 1) . Moreover, the side chains of 7 of these 8 residues interact directly with Ca 2+ . In contrast, only 4 of the 21 unique variants in ExAC (G24, I28, A103, and A104) reside within an EF hand calcium-binding loop; however, none of them involve a residue whose side chain interacts directly with calcium ( Figure 1 ). In addition, there are 2 extremely rare protein truncating variants (G42* and D51Gfs*5) present in the ExAC browser that were identified in 2 of 60 706 individuals. However, given the severity of CaM-related LQTS, this would suggest that having a nonfunctioning CaM protein from 1 of 6 CaM-generating alleles is not pathogenic. 14
Demographic and Clinical Characteristics of Patients Harboring CaM Variants
Compared with our original LQTS referral cohort that comprised 541 patients in 2005 where the average age at diagnosis was 24±16 years, the average QTc was 482±57 ms, and 12% had cardiac arrest 19 ; Table 3 details the differences between LQT1-3-positive and LQT1-3-negative cases in this original cohort, 19 the CaM-positive cases herein, and the CaM-negative cases that still remain genetically elusive. The average age of CaM-positive patients was significantly younger (0.8 years) compared with CaM-negative (23 years; P<0.01; Figure 2A ; Table 3 ). 19 In addition, the yield of CaM variants was significantly higher in patients <5 years of age (5/9, 56%) compared with patients ≥5 years of age (0/29, 0%, P<0.001; Figure 2B ). The average QTc was significantly longer in CaM-positive patients (676±36 ms) compared with CaM-negative patients (514±9 ms; P<0.0001; Figure 2C ; Table 3 ). 19 In addition, the occurrence of cardiac arrest was significantly higher in CaMpositive patients (5/5; 100%) compared with CaM-negative patients (8/33; 24%, P<0.01; Figure 2D ; Table 3 ). 19
Functional Characterization
Because p.D130G and p.F142L are disruptive functionally (Table 2) , 7,10,11 we confidently conclude that these variants are responsible for the LQTS phenotype observed in our patients. Although p.D130V is novel, we think that because glycine (G) and valine (V) are replacing a critical negatively charged aspartic acid (D) known to interact with the positively charged calcium ion (Figure 1 ), p.D130V will functionally and clinically mimic p.D130G. The p.E141G variant was the only variant affecting a novel residue, and we therefore characterized it functionally in this study.
E141G-CaM Impairs Ca 2+ Binding by CaM
In line with previous observations, the p.E141G variant, located in EF hand IV of the C domain (Figure 1 ), decreased the Ca 2+ affinity of the C domain (by 11-fold) but did not significantly alter the Ca 2+ affinity of the N domain ( Figure 3A ).
E141G-CaM Disrupts Ca V 1.2's CDI
The previously published LQTS-associated CaM variants significantly impaired Ca V 1.2 CDI, leading to a loss of inactivation. 10, 11 Therefore, we examined the effects of E141G-CaM on Ca V 1.2 in a heterologous expression system. Typical Ca V 1.2 tracings of voltage-dependent activation from Ca V 1.2 with GFP-EV, WT-and E141G-CaM are shown in Figure 3B with holding potential at −90 mV to various depolarization potentials. Current-voltage relationship shows that E141G-CaM did not change Ca V 1.2 peak current density ( Figure 3C ). However, E141G-CaM shifted Ca V 1.2 V 1/2 of steady-state inactivation 1.9 mV from −16.8±0.23 mV (Ca V 1.2+WT-CaM; n=11) to −14.9±0.27 mV (Ca V 1.2+E141G-CaM; n=9). The E141G-CaM also shifted Ca V 1.2 V 1/2 of activation −3.9 mV CaM indicates calmodulin; LQTS, long QT syndrome; and QTc, corrected QT interval. *LQT1-3 positive represents individuals who were positive for putative pathogenic variants in KCNQ1, KCNH2, or SCN5A from a larger cohort of 541 unrelated individuals with LQTS from a previously published study. 19 †LQT1-3 negative represents individuals who were negative for putative pathogenic variants in KCNQ1, KCNH2, or SCN5A from a larger cohort of 541 unrelated individuals with LQT from a previously published study. 19 Figure 3D ). Ca V 1.2+E141G-CaM exhibited much slower fast and slow decay time across the voltages +10 mV to +50 mV compared with Ca V 1.2+WT-CaM (n=10 for each group, P<0.05; Figure 3E -3F). Typical Ca V 1.2 current tracings from Ca V 1.2+EV, WT-CaM, and E141G-CaM are shown in Figure 4A . E141G-CaM increased Ca V 1.2's persistent current 7.1-fold from 2.1±0.5% (Ca V 1.2+WT-CaM; n=9) to 17.0±3.0% (Ca V 1.2+E141G-CaM; n=10, P<0.05; Figure 4B ).
We next tested the effect of E141G-CaM in native murine ventricular myocytes. As in our heterologous expression system, E141G-CaM drastically impaired Ca V 1.2 current inactivation without affecting peak currents ( Figure 4C-4E) . Even a 25% fraction of E141G-CaM in the presence of 75% WT-CaM was sufficient to significantly impair the Ca V 1.2 inactivation, which is consistent with a dominant-negative effect.
E141G-CaM Accentuates Na V 1.5 Late Current
Next, we determined if E141G-CaM affected the electrophysiological characteristics of Na V 1.5. Typical I Na tracings of voltage-dependent activation from Na V 1.5 with GFP-EV, WT-and E141G-CaM are shown in Figure 5A with holding potential at -100 mV to various depolarization potentials. Current-voltage relationship shows that WT-and E141G-CaM did not change Na V 1.5 peak current density, voltage-dependent inactivation or activation, or decay time ( Figure 5B-5D ).
Typical Na V 1.5 late current tracings from Na V 1.5 with EV, WT-, E141G-CaM, and WT-CaM+E141G-CaM are shown in Figure 5E . E141G-CaM increased Na V 1.5's late current 1.7fold from 0.13±0.01% (Na V 1.5+WT-CaM; n=8) to 0.35±0.06% (Na V 1.5+E141G-CaM; n=10; P<0.05; Figure 5F ). However, when WT-CaM was coexpressed with E141G-CaM, there was no longer an effect on the Na V 1.5 peak late current ( Figure 5E-5F ). This result suggests that unlike for Cav1.2, there was no functional dominance of E141G-CaM in the regulation of Na V 1.5 late currents.
E141G-CaM Has No Effect on RyR2 Ca 2+ Release Channels and SR Ca 2+ Handling
CaM variants have also been identified in patients with CPVT, 18 leading to activation of RyR2 SR Ca 2+ release channels. 3 However, Steady-state inactivation was determined from a holding potential of −90 mV to prepulse of 20 mV in 10 mV increments with 10-s duration followed by a test pulse of 30 mV with 500-ms duration. I/I max represents normalized calcium current and G/G max represents normalized conductance. Fast (E) and slow (F) decay time of Ca V 1.2+EV, Ca V 1.2+WT-CaM, and Ca V 1.2+E141G-CaM. *P<0.05 vs Ca V 1.2+WT-CaM.
to date, the known LQTS-associated CaM variants have exerted no effect or only slightly reduced RyR2 Ca 2+ release channel activity. 20 Therefore, we determined the effect of E141G-CaM on intracellular Ca 2+ handling by measuring Ca 2+ sparks (a measure of RyR2 Ca 2+ release channel activity) and found that E141G-CaM had no effect on Ca 2+ sparks and SR Ca 2+ content ( Figure 6 ).
Discussion
Our examination of 38 patients with genetically elusive LQTS identified 5 individuals (13.2%) that harbored variants in either CALM1 or CALM2. Two of the identified variants, p.D130G and p.F142L, had been published previously in other cases of LQTS, 7 1 variant represented a novel amino acid change at a previously described position, p.D130V, and the final variant, p.E141G, was novel. Within our cohort, CaM variants were over-represented significantly when compared with the publically available databases in essentially modified case:control analysis, which provides additional evidence that single amino acid substitutions within CaM, particularly those involving calcium-interacting residues in the C domain, are not well tolerated.
When examining the clinical characteristics of these 5 patients harboring CaM variants, we found that they had an early age at onset with the average age of onset at 10 months, average QTc of 676±36 ms, and all experienced cardiac arrest ( Figure 2 ; Table 3 ). 19 Moreover, all CaM variants were shown to occur as de novo when parental DNA was available for testing, thus supporting the malignant nature of LQTS-related CaM variants. These clinical characteristics seemed even more severe than those of the previously published LQT1-3 genotype-positive and LQT1-3 genotype-negative LQTS (Table 3) , 19 and the previously described LQTS 7 and LQTS/CPVT 8 patients with CaM variants (n=10), where the average age at diagnosis was 3 years, the average QTc was 591±22 ms, and 60% experienced cardiac arrest (Table 2) . However, if we separate the previously described CaM-positive patients into 2 categories, LQTS/CPVT overlap phenotypes and a pure LQTS phenotype, it becomes more apparent that LQTS/CPVT patients (n=3) 8 may be less severe, as the average age at diagnosis was 7 years, the average QTc was 519±53 ms, with only 33% experiencing cardiac arrest. In contrast, the patients with a pure LQTS phenotype (n=7) were similar to our LQTS CaM-positive patients, with an average age at diagnosis of 14 months, an average QTc of 622±20 ms, and with 86% experiencing cardiac arrest. This provides evidence that CaM-mediated LQTS is severe and it may be important to delineate these phenotypes, as they may present with different disease severities, and the phenotypic presentation may be regulated by distinct underlying mechanisms. Therefore, continued studies will be necessary to elucidate the key differences between CaM variants and their associated phenotypes. In addition, children with CaMmediated LQTS who survive will need ongoing surveillance for the potential development of a cardiomyopathy as 2 of the CaM-variant-positive children who have survived past 5 years of age, and one of the deceased patients on autopsy, had developed dilated cardiomyopathy. It is possible that the Ca V 1.2's impaired CDI may contribute to diastolic calcium excess that could precipitate cardiomyopathic structural remodeling.
CaM modulates the activity of several different ion channels by sensing and transducing Ca 2+ signals. When Ca 2+ levels are raised, CaM binds up to 4 calcium ions, which stabilize an open conformation within each domain that mediates interactions with CaM's targets. Hence, we first examined the effects of the p.E141G variant on the Ca 2+ affinity of CaM and found that this mutant resulted in an 11-fold reduction in the Ca 2+ affinity of the C domain. These results are comparable with the Ca 2+ -binding impairments caused by the 8 variants previously associated with LQTS or LQTS/CPVT overlap phenotypes (5-to 54-fold increased dissociation of Ca 2+ in the C domain, Table 2) , 7, 10, 18 suggesting that impaired Ca 2+binding properties in the C domain is a common underlying pathomechanism of LQTS-associated CaM variants.
These disrupted Ca 2+ affinities have direct implications on Ca V 1.2's CDI. Typically, Ca V 1.2 is inactivated with increasing Ca 2+ concentrations via a mechanism mediated by the binding of CaM. The altered Ca 2+ -binding properties of CaM, such as with E141G-CaM, would therefore be expected to impair Ca V 1.2's CDI. Using whole-cell patch-clamp experiments, we found that E141G-CaM shifted inactivation 1.9 mV. These findings were replicated in native ventricular myocytes where E141G-CaM again reduced Ca V 1.2 inactivation, which closely parallels what has been noted previously with the other LQTS-associated CaM variants. 10, 11 Because there are 3 calmodulin genes expressed in the heart, which each encode for an identical protein, our heterozygous variant only affects 1 of 6 of the calmodulin alleles. Therefore, we examined the E141G-CaM variant at reduced levels (25:75; Figure 5 . E141G-calmodulin (CaM) leads to increased Na V 1.5 late current. A, Representative tracings of whole-cell Na V 1.5 current from TSA201 cells expressing Na V 1.5+empty vector (EV), Na V 1.5+WT-CaM, and Na V 1.5+E141G-CaM determined from a holding potential of −100 mV to testing potential of +90 mV in 10 mV increments with 24-ms duration. B, Current-voltage relationship for Na V 1.5+EV, Na V 1.5+WT-CaM, and Na V 1.5+E141G-CaM. All values represent mean±SEM. C, Inactivation-activation curves of Na V 1.5+EV, Na V 1.5+WT-CaM, and Na V 1.5+E141G-CaM (n=13-15). Steady-state inactivation obtained from a holding potential of −120 mV to prepulse of 0 mV in 10 mV increments with 976-ms duration followed by a test pulse of 0 mV with 24-ms duration. I/I max represents normalized sodium current, G/G max represents normalized conductance. D, Fast and slow decay time of Na V 1.5+EV, Na V 1.5+WT-CaM, and Na V 1.5+E141G-CaM. E, Representative tracings of Na V 1.5 late current from Na V 1.5+EV, Na V 1.5+WT-CaM, Na V 1.5+E141G-CaM, and Na V 1.5+WT-CaM+E141G-CaM determined from a holding potential of −120 to −20 mV with 700-ms duration. F, Group data showing Na V 1.5 late current normalized to peak (%) for Na V 1.5+EV, Na V 1.5+WT-CaM, Na V 1.5+E141G-CaM, and Na V 1.5+WT-CaM+E141G-CaM. *P<0.05 vs Na V 1.5+WT-CaM. mutant:WT), which also maintained a significant effect on inactivation. This suggests that p.E141G has a dominant-negative effect and is capable of causing the disease phenotype.
In addition to Ca V 1.2, it has been established previously that CaM modulates cardiac sodium channel inactivation. 21 Previously, Yin et al 11 found that LQTS-associated CaM variants (p.D96V, p.D130G, and p.F142L) did not affect Na V 1.5; however, p.D130G led to a 7.5-fold increase in fetal Na V 1.5 late current. They hypothesized that because CaM-mediated LQTS has an early age of onset, the variants may only affect the fetal isoform of the sodium channel. However, because there have been associations of CaM with the adult isoform of Na V 1.5, we wanted to determine whether E141G-CaM may have an effect on channel gating function. Our studies showed that the p.E141G variant led to a 1.7-fold increase in Na V l.5 late current when expressed as a homozygote. This makes our E141G-CaM variant the first CaM variant shown to affect the adult isoform of the cardiac sodium channel. Interestingly, however, when p.E141G was expressed with wild-type CaM-mimicking a heterozygote patient-the Na V 1.5 late current was normalized. This differs from the effect of E141G-CaM on Ca V 1.2, where even a 3-fold excess of WT CaM failed to normalize Ca V 1.2 inactivation.
It has been established that CPVT-associated CaM variants 18 affect the functioning of RYR2-encoded ryanodine receptor (RyR2), leading to greater open probability of the channel. 3 Because one previously reported LQTS-associated CaM variant (p.N98S) also activates RyR2 and can cause CPVT as well as LQTS, 3 we examined the effect of p.E141G on RyR2 Ca 2+ release channel activity. The p.E141G variant had no effect on Ca 2+ sparks, a measure of RyR2 Ca 2+ release channel activity and did not affect SR Ca 2+ content. Hence, our results continue to support the emerging evidence that LQTS-associated CaM variants do not affect RyR2, whereas CPVT-associated CaM variants perturb RyR2 function.
Conclusions
We have identified a novel CaM variant p.E141G, which like other LQTS-associated CaM variants, disrupts Ca 2+ binding and leads to increased Ca V 1.2 window/persistent current. In addition, p.E141G is the first CaM variant identified to also affect the adult Na V 1.5 isoform, leading to increased sodium late current. Overall, we found that 13% of genetically elusive patients with LQTS harbored a functionally significant CaM variant. The phenotypic characteristics of the CaM-positive individuals from our cohort, combined with the other published cases of LQTSassociated CaM variants, suggest that patients with LQTS harboring variants in either CALM1-, CALM2-, or CALM3-encoded CaM present early in life with profound QT prolongation and have a high predilection for cardiac arrest and sudden death. The existing gene panels for LQTS genetic testing should now be expanded to include CALM1, CALM2, and CALM3.
CLINICAL PERSPECTIVE
Recently, pathological variants in 3 genes (CALM1, CALM2, and CALM3) encoding for 100% identical calmodulin protein have been associated with early onset long QT syndrome (LQTS). This report sought to characterize the spectrum and prevalence of calmodulin variants in an unrelated cohort of 38 patients with heretofore genetically elusive LQTS. Overall, 5 of these cases harbored rare pathogenic variants in 1 of the 3 calmodulin encoding genes. Two previously published variants (p.D130G and p.F142L identified twice) and 2 novel (p.D130V and p.E141G) variants were identified. Because p.D130V was allelic with a previously characterized pathogenic variant in calmodulin (p.D130G), we elected to functionally characterize the other novel variant. This variant, p.E141G, disrupted Ca 2+ binding and led to altered Ca v 1.2 window current, similar to previously characterized calmodulin variants, consistent with LQTS pathogenicity. Closer examination of the phenotypic sequelae of these 5 patients with calmodulin-mediated LQTS highlighted that such individuals present early in life, have profound QT prolongation, and have a high predilection for cardiac arrest and sudden death when compared with LQTS patients without pathogenic calmodulin variants. These findings replicated what has been previously described in the literature, and there are now at least 10 described variants in one of the 3 calmodulin genes associated with LQTS. Taken altogether, patients with calmodulin-associated LQTS are more severe phenotypically than typical LQTS and genetic testing of all 3 calmodulin genes is warranted when there is evidence of severe, early onset LQTS.
